Macrolide Antibiotics:
The current state of research, development, and use of macrolides as a treatment option for bacterial infections is the subject of this monograph. Macrolides, whose first representative (erythromycin) was introduced into the market in the 1950s, have been optimised by various companies into effectiv...
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Basel
Birkhäuser Basel
2002
|
| Schriftenreihe: | Milestones in Drug Therapy
|
| Schlagworte: | |
| Online-Zugang: | DE-355 Volltext |
| Zusammenfassung: | The current state of research, development, and use of macrolides as a treatment option for bacterial infections is the subject of this monograph. Macrolides, whose first representative (erythromycin) was introduced into the market in the 1950s, have been optimised by various companies into effective, safe, and convenient treatments with overwhelming success. Various compounds, such as azithromycin, clarithromycin, erythromycin, and roxithromycin, are in current effective use for treatment of infections mainly of the respiratory, gastrointestinal, and urogenital tracts and skin and soft tissues. A highly competitive research environment and critical medical need for improved macrolides have led to various new scaffolds and derivatives such as the ketolides ABT-773 and telithromycin, which are in development or in the regulatory process for market approval. The individual chapters cover aspects of microbiology, clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and chemistry. They are written by leading experts in their respective fields. Thus, readers - whether they are professionals in the pharmaceutical industry, physicians treating infections, or biochemists, chemists, pharmacologists or microbiologists at hospitals, health institutes, or universities - will find a detailed and up-to-date knowledge base about current research activities and a sound, stimulating overview of the compound class |
| Beschreibung: | 1 Online-Ressource (X, 323 p) |
| ISBN: | 9783034881050 |
| DOI: | 10.1007/978-3-0348-8105-0 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV046148743 | ||
| 003 | DE-604 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 190906s2002 |||| o||u| ||||||eng d | ||
| 020 | |a 9783034881050 |9 978-3-0348-8105-0 | ||
| 024 | 7 | |a 10.1007/978-3-0348-8105-0 |2 doi | |
| 035 | |a (ZDB-2-SBL)978-3-0348-8105-0 | ||
| 035 | |a (OCoLC)1119148442 | ||
| 035 | |a (DE-599)BVBBV046148743 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 082 | 0 | |a 615 |2 23 | |
| 084 | |a VS 8720 |0 (DE-625)147720:253 |2 rvk | ||
| 084 | |a XI 3750 |0 (DE-625)153001:13129 |2 rvk | ||
| 245 | 1 | 0 | |a Macrolide Antibiotics |c edited by Wolfgang Schönfeld, Herbert A. Kirst |
| 264 | 1 | |a Basel |b Birkhäuser Basel |c 2002 | |
| 300 | |a 1 Online-Ressource (X, 323 p) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Milestones in Drug Therapy | |
| 520 | |a The current state of research, development, and use of macrolides as a treatment option for bacterial infections is the subject of this monograph. Macrolides, whose first representative (erythromycin) was introduced into the market in the 1950s, have been optimised by various companies into effective, safe, and convenient treatments with overwhelming success. Various compounds, such as azithromycin, clarithromycin, erythromycin, and roxithromycin, are in current effective use for treatment of infections mainly of the respiratory, gastrointestinal, and urogenital tracts and skin and soft tissues. A highly competitive research environment and critical medical need for improved macrolides have led to various new scaffolds and derivatives such as the ketolides ABT-773 and telithromycin, which are in development or in the regulatory process for market approval. The individual chapters cover aspects of microbiology, clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and chemistry. They are written by leading experts in their respective fields. Thus, readers - whether they are professionals in the pharmaceutical industry, physicians treating infections, or biochemists, chemists, pharmacologists or microbiologists at hospitals, health institutes, or universities - will find a detailed and up-to-date knowledge base about current research activities and a sound, stimulating overview of the compound class | ||
| 650 | 4 | |a Pharmacology/Toxicology | |
| 650 | 4 | |a Infectious Diseases | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Medical Microbiology | |
| 650 | 4 | |a Toxicology | |
| 650 | 4 | |a Emerging infectious diseases | |
| 650 | 4 | |a Immunology | |
| 650 | 4 | |a Microbiology | |
| 650 | 0 | 7 | |a Makrolidantibiotikum |0 (DE-588)4168682-2 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4143413-4 |a Aufsatzsammlung |2 gnd-content | |
| 689 | 0 | 0 | |a Makrolidantibiotikum |0 (DE-588)4168682-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Schönfeld, Wolfgang |4 edt | |
| 700 | 1 | |a Kirst, Herbert A. |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034894388 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783764361860 |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9783034881067 |
| 856 | 4 | 0 | |u https://doi.org/10.1007/978-3-0348-8105-0 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-2-SBL | ||
| 940 | 1 | |q ZDB-2-SBL_2000/2004 | |
| 943 | 1 | |a oai:aleph.bib-bvb.de:BVB01-031528920 | |
| 966 | e | |u https://doi.org/10.1007/978-3-0348-8105-0 |l DE-355 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1811034640376397824 |
|---|---|
| adam_text | |
| any_adam_object | |
| author2 | Schönfeld, Wolfgang Kirst, Herbert A. |
| author2_role | edt edt |
| author2_variant | w s ws h a k ha hak |
| author_facet | Schönfeld, Wolfgang Kirst, Herbert A. |
| building | Verbundindex |
| bvnumber | BV046148743 |
| classification_rvk | VS 8720 XI 3750 |
| collection | ZDB-2-SBL |
| ctrlnum | (ZDB-2-SBL)978-3-0348-8105-0 (OCoLC)1119148442 (DE-599)BVBBV046148743 |
| dewey-full | 615 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615 |
| dewey-search | 615 |
| dewey-sort | 3615 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| doi_str_mv | 10.1007/978-3-0348-8105-0 |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>00000nmm a2200000zc 4500</leader><controlfield tag="001">BV046148743</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2002 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783034881050</subfield><subfield code="9">978-3-0348-8105-0</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-3-0348-8105-0</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-3-0348-8105-0</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119148442</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148743</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VS 8720</subfield><subfield code="0">(DE-625)147720:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XI 3750</subfield><subfield code="0">(DE-625)153001:13129</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Macrolide Antibiotics</subfield><subfield code="c">edited by Wolfgang Schönfeld, Herbert A. Kirst</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel</subfield><subfield code="b">Birkhäuser Basel</subfield><subfield code="c">2002</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (X, 323 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Milestones in Drug Therapy</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The current state of research, development, and use of macrolides as a treatment option for bacterial infections is the subject of this monograph. Macrolides, whose first representative (erythromycin) was introduced into the market in the 1950s, have been optimised by various companies into effective, safe, and convenient treatments with overwhelming success. Various compounds, such as azithromycin, clarithromycin, erythromycin, and roxithromycin, are in current effective use for treatment of infections mainly of the respiratory, gastrointestinal, and urogenital tracts and skin and soft tissues. A highly competitive research environment and critical medical need for improved macrolides have led to various new scaffolds and derivatives such as the ketolides ABT-773 and telithromycin, which are in development or in the regulatory process for market approval. The individual chapters cover aspects of microbiology, clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and chemistry. They are written by leading experts in their respective fields. Thus, readers - whether they are professionals in the pharmaceutical industry, physicians treating infections, or biochemists, chemists, pharmacologists or microbiologists at hospitals, health institutes, or universities - will find a detailed and up-to-date knowledge base about current research activities and a sound, stimulating overview of the compound class</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Infectious Diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medical Microbiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Emerging infectious diseases</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Microbiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Makrolidantibiotikum</subfield><subfield code="0">(DE-588)4168682-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Makrolidantibiotikum</subfield><subfield code="0">(DE-588)4168682-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schönfeld, Wolfgang</subfield><subfield code="4">edt</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kirst, Herbert A.</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034894388</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783764361860</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9783034881067</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-3-0348-8105-0</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031528920</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-3-0348-8105-0</subfield><subfield code="l">DE-355</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| genre | (DE-588)4143413-4 Aufsatzsammlung gnd-content |
| genre_facet | Aufsatzsammlung |
| id | DE-604.BV046148743 |
| illustrated | Not Illustrated |
| indexdate | 2024-09-24T00:20:22Z |
| institution | BVB |
| isbn | 9783034881050 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031528920 |
| oclc_num | 1119148442 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | 1 Online-Ressource (X, 323 p) |
| psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
| publishDate | 2002 |
| publishDateSearch | 2002 |
| publishDateSort | 2002 |
| publisher | Birkhäuser Basel |
| record_format | marc |
| series2 | Milestones in Drug Therapy |
| spelling | Macrolide Antibiotics edited by Wolfgang Schönfeld, Herbert A. Kirst Basel Birkhäuser Basel 2002 1 Online-Ressource (X, 323 p) txt rdacontent c rdamedia cr rdacarrier Milestones in Drug Therapy The current state of research, development, and use of macrolides as a treatment option for bacterial infections is the subject of this monograph. Macrolides, whose first representative (erythromycin) was introduced into the market in the 1950s, have been optimised by various companies into effective, safe, and convenient treatments with overwhelming success. Various compounds, such as azithromycin, clarithromycin, erythromycin, and roxithromycin, are in current effective use for treatment of infections mainly of the respiratory, gastrointestinal, and urogenital tracts and skin and soft tissues. A highly competitive research environment and critical medical need for improved macrolides have led to various new scaffolds and derivatives such as the ketolides ABT-773 and telithromycin, which are in development or in the regulatory process for market approval. The individual chapters cover aspects of microbiology, clinical use and experience, pharmacokinetics, pharmacodynamics, biochemistry, and chemistry. They are written by leading experts in their respective fields. Thus, readers - whether they are professionals in the pharmaceutical industry, physicians treating infections, or biochemists, chemists, pharmacologists or microbiologists at hospitals, health institutes, or universities - will find a detailed and up-to-date knowledge base about current research activities and a sound, stimulating overview of the compound class Pharmacology/Toxicology Infectious Diseases Immunology Medical Microbiology Toxicology Emerging infectious diseases Microbiology Makrolidantibiotikum (DE-588)4168682-2 gnd rswk-swf (DE-588)4143413-4 Aufsatzsammlung gnd-content Makrolidantibiotikum (DE-588)4168682-2 s DE-604 Schönfeld, Wolfgang edt Kirst, Herbert A. edt Erscheint auch als Druck-Ausgabe 9783034894388 Erscheint auch als Druck-Ausgabe 9783764361860 Erscheint auch als Druck-Ausgabe 9783034881067 https://doi.org/10.1007/978-3-0348-8105-0 Verlag URL des Erstveröffentlichers Volltext |
| spellingShingle | Macrolide Antibiotics Pharmacology/Toxicology Infectious Diseases Immunology Medical Microbiology Toxicology Emerging infectious diseases Microbiology Makrolidantibiotikum (DE-588)4168682-2 gnd |
| subject_GND | (DE-588)4168682-2 (DE-588)4143413-4 |
| title | Macrolide Antibiotics |
| title_auth | Macrolide Antibiotics |
| title_exact_search | Macrolide Antibiotics |
| title_full | Macrolide Antibiotics edited by Wolfgang Schönfeld, Herbert A. Kirst |
| title_fullStr | Macrolide Antibiotics edited by Wolfgang Schönfeld, Herbert A. Kirst |
| title_full_unstemmed | Macrolide Antibiotics edited by Wolfgang Schönfeld, Herbert A. Kirst |
| title_short | Macrolide Antibiotics |
| title_sort | macrolide antibiotics |
| topic | Pharmacology/Toxicology Infectious Diseases Immunology Medical Microbiology Toxicology Emerging infectious diseases Microbiology Makrolidantibiotikum (DE-588)4168682-2 gnd |
| topic_facet | Pharmacology/Toxicology Infectious Diseases Immunology Medical Microbiology Toxicology Emerging infectious diseases Microbiology Makrolidantibiotikum Aufsatzsammlung |
| url | https://doi.org/10.1007/978-3-0348-8105-0 |
| work_keys_str_mv | AT schonfeldwolfgang macrolideantibiotics AT kirstherberta macrolideantibiotics |